Revenue Breakdown
Composition ()
No data
Revenue Streams
QuidelOrtho Corp (QDEL) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Labs, accounting for 53.4% of total sales, equivalent to $373.80M. Other significant revenue streams include Point-of-Care and Immunohematology. Understanding this composition is critical for investors evaluating how QDEL navigates market cycles within the Advanced Medical Equipment & Technology industry.
Profitability & Margins
Evaluating the bottom line, QuidelOrtho Corp maintains a gross margin of 41.13%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 6.46%, while the net margin is -104.73%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively QDEL converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, QDEL competes directly with industry leaders such as LMAT and ESTA. With a market capitalization of $1.85B, it holds a significant position in the sector. When comparing efficiency, QDEL's gross margin of 41.13% stands against LMAT's 75.28% and ESTA's 70.09%. Such benchmarking helps identify whether QuidelOrtho Corp is trading at a premium or discount relative to its financial performance.
